Michelle Geller

Michelle L Geller brings a wealth of expertise to her current role as Global Development Senior Medical Scientist at Amgen, where she plays a pivotal role in advancing the company's innovative therapeutic pipeline. With over 27 years of experience in healthcare—spanning clinical medicine, medical affairs, and the pharmaceutical industry—Michelle offers a comprehensive perspective on patient safety, clinical development, and regulatory compliance. Her extensive background in infectious diseases, nephrology, and oncology uniquely positions her to oversee complex safety assessments across diverse therapeutic areas.

In her capacity at Amgen, Michelle leads critical initiatives within the Global Patient Safety Organization, ensuring the integrity of pharmacovigilance (PV) operations worldwide. Her expertise encompasses therapeutic area safety, PV compliance, and the development of safety surveillance strategies that support the lifecycle management of innovative biologics and small molecules. She collaborates closely with cross-functional teams—including clinical development, medical affairs, and regulatory affairs—to integrate safety data insights into the broader context of drug development and post-marketing surveillance.

Michelle’s leadership extends to fostering centers of excellence in PV, driving continuous improvement in safety monitoring, and ensuring adherence to international safety standards. Her skills in medical writing and teaching hospitals facilitate effective communication of safety findings to diverse stakeholders, including regulatory agencies and healthcare providers. With her deep understanding of biotechnology and direct patient care, Michelle remains committed to safeguarding patient well-being while advancing Amgen’s mission to serve patients through innovative therapies. Her strategic insights and operational expertise make her a key driver in shaping the future of global drug safety and development.